Juva Life Q1 2022 Revenue Grows 97% YoY
Juva Life Q1 2022 Revenue Grows 97% YoY
Juva Life Inc. (OTCQB:JUVAF) (CSE:JUVA) (FRANKFURT:4VV) released highlights of its financial and operating results for Q1 of 2022.
JUVA Life Inc.(場外交易代碼：JUVAF)(CSE：JUVA)(法蘭克福：4VV)發佈了2022年第一季度的財務和經營業績摘要。
$1.16 million of revenue was generated in Q1 2022, almost double the $580,000 of revenue in the same period for the prior year. This growth was driven by increased sales in both its retail business operations as well as sales of wholesale bulk cannabis flower.
第一季度創收116萬美元2022年，幾乎是去年同期58萬美元收入的兩倍。這一增長是由其零售業務以及批發散裝大麻花銷售的增長推動的。
Net loss for the quarter decreased from $5.5 million in Q1 2021 to $3 million in Q1 2022.
本季度淨虧損減少2021年第一季度為550萬美元至300萬美元在2022年第一季度。
In the first quarter of 2022, Juva advanced JUVA-019, a proprietary novel compound that has previously demonstrated potent anti-inflammatory properties in phenotypic assays of inflammation, from discovery into preclinical development. It also advanced JUVA-041, a second proprietary novel compound into preclinical development, further substantiating the company's discovery strategy and technology platform.
2022年第一季度，Juva將JUVA-019從發現到臨牀前開發，JUVA-019是一種專利新型化合物，以前在炎症的表型分析中顯示出強大的抗炎特性。它還將第二種專利新型化合物JUVA-041推進到臨牀前開發，進一步證實了公司的發現戰略和技術平臺。
Juva Life has filed patents on both compounds and plans to advance them through the standardized clinical stage gate in the coming months. Also on the clinical side of the company, Juva launched the Journal App that offers cannabis users a daily tracking solution to monitor how their cannabis consumption affects their personal health and wellness, furthering Juva's mission of proving the therapeutic value of cannabis.
JUVA Life已經為這兩種化合物申請了專利，並計劃在未來幾個月內推動它們通過標準化的臨牀階段。同樣在公司的臨牀方面，Juva推出了日誌應用程序這為大麻使用者提供了一個每日跟蹤解決方案，以監測他們的大麻消費如何影響他們的個人健康和健康，進一步推動Juva證明大麻的治療價值的使命。
Additionally, the company completed the final phase of construction of its 30,000-square-foot Stockton cultivation facility, which more than doubled the growing capacity of the facility without adding additional costs, and maximizing the facility's cultivation systems.
此外，該公司還完成了佔地30,000平方英尺的斯托克頓種植設施的最後階段建設，在不增加額外成本的情況下將設施的增長能力增加了一倍以上，並最大限度地提高了設施的種植系統。
"As we move to the second half of the year, we are feeling extremely confident about our progress in both our life sciences research and cannabis operations," stated Doug Chloupek, CEO and founder of Juva. "Our research team is moving at an unparalleled pace in proving the potential therapeutic value of both of our lead candidates, JUVA-019 and JUVA-041. We have already seen extremely promising preclinical results in their ability to inhibit inflammation, and we are moving them forward in their clinical pipeline as quickly as possible."
他説：“隨着我們進入下半年，我們對我們在生命科學研究和大麻行動方面的進展非常有信心。”道格·克洛佩克，Juva的首席執行官兼創始人。我們的研究團隊正在以無與倫比的速度證明我們的兩種主要候選藥物JUVA-019和JUVA-041的潛在治療價值。我們已經在它們抑制炎症的能力方面看到了非常有希望的臨牀前結果，我們正在儘快推動它們在臨牀方面的進展。“
"On the cannabis operations side, our cultivation facility in Stockton is fully complete and firing on every cylinder. The delivery business is continuing to grow, and we are so excited to have received one of the first and only retail licenses in Redwood City. All in all, Q1 was a great first quarter for Juva, and we are looking forward to sharing our Q2 results in short order."
在大麻業務方面，我們在斯托克頓的種植設施已經完全完工，每一個氣缸都在點火。遞送業務正在繼續增長，我們很高興獲得了紅杉城第一批也是唯一一份零售許可證。總而言之，第一季度對Juva來説是一個很棒的第一季度，我們期待着在短期內分享我們第二季度的結果。
Related News
相關新聞
Is Market Pressure Hindering Cannabis Real Estate Investment? Ask Rob Sechrist At The Cannabis Capital Conference In September
市場壓力是否阻礙了大麻房地產投資？問問9月大麻首都會議上的Rob Sechrist
3 Financial Players To Watch In Cannabis: Alternative Funding Options For A Burgeoning Industry
大麻行業值得關注的3個金融參與者：新興行業的替代融資選擇
How Do Cannabis Companies Get Started When They Have No Money? Ask Judy Rinkus At The Cannabis Capital Conference In September
當大麻公司沒有錢的時候，他們是如何開始的？在9月的大麻首都會議上問問朱迪·林庫斯
譯文內容由第三人軟體翻譯。